Allergies News and Research

Latest Allergies News and Research

Defective epithelial barrier responsible for up to two billion chronic diseases

Humans are exposed to a variety of toxins and chemicals every day. According to the epithelial barrier hypothesis, exposure to many of these substances damages the epithelium, the thin layer of cells that covers the surface of our skin, lungs and intestine. Defective epithelial barriers have been linked to a rise in almost two billion allergic, autoimmune, neurodegenerative and psychiatric diseases.

6 May 2021

New method for qualifying safe drug dosing regimens in pediatrics

Determining safe yet effective drug dosages for children is an ongoing challenge for pharmaceutical companies and medical doctors alike.

6 May 2021

Study: Second vaccine dose still makes organ transplant recipients vulnerable to COVID-19

In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 - the virus that causes COVID 19 - confers some protection for people who have received solid organ transplants, it's still not enough to enable them to dispense with masks, physical distancing and other safety measures.

6 May 2021

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health

A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.

5 May 2021

Asthma Awareness: Fighting Asthma in 2021

In light of World Asthma Day, News-Medical interviewed Dr. Samantha Walker from Asthma UK and the British Lung Foundation about fighting asthma in 2021.

5 May 2021

New testing technology can accurately differentiate between viral and bacterial infections

When patients complain of coughing, runny nose, sneezing and fever, doctors are often stumped because they have no fundamental tool to identify the source of the respiratory symptoms and guide appropriate treatments.

4 May 2021

ATS publishes new clinical practice guideline on community-acquired pneumonia

In its latest clinical practice guideline on community-acquired pneumonia the American Thoracic Society's guidelines panel addresses the use of nucleic acid-based testing for non-influenza viral pathogens.

4 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Risk factors for long COVID-19 in children

A new study describes the risk factors and outcomes of “long COVID-19” in a cohort of children who were hospitalized with COVID-19.

29 Apr 2021

Texas A&M AgriLife receives grant to support research on bacteriophage therapy

The National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has awarded $2.5 million in grants to support research on bacteriophage therapy, and Texas A&M AgriLife Research is among the grant recipients.

29 Apr 2021

Immunocompromised children and young adults may experience prolonged SARS-CoV-2 infection

Children and young adults with compromised immune systems, such as those undergoing cancer treatment, may experience a prolonged period of infection with SARS-CoV-2, the virus that causes COVID-19, and the extended duration of infection may increase the incidence of mutations.

29 Apr 2021

Long COVID also affects children, study finds

Older children and children with allergies or asthma were found to have greater odds of having persistent symptoms even months after recovery.

28 Apr 2021

Clinical trial to test existing antibiotic for treating serious S. aureus infections begins

A clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S. aureus) bacteremia has begun.

27 Apr 2021

Heat treatment for less than a second completely inactivates SARS-CoV-2

Arum Han, professor in the Department of Electrical and Computer Engineering at Texas A&M University, and his collaborators have designed an experimental system that shows exposure of SARS-CoV-2 to a very high temperature, even if applied for less than a second, can be sufficient to neutralize the virus so that it can no longer infect another human host.

27 Apr 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Corticosteroids not recommended to treat smell loss due to Covid-19, study shows

Steroids should not be used to treat smell loss caused by Covid-19 according to an international group of smell experts, including Prof Carl Philpott from the University of East Anglia.

27 Apr 2021

Study to evaluate how people with immune system deficiencies respond to COVID-19 vaccination

A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland.

26 Apr 2021

NIAID establishes a clinical research network to improve understanding of childhood asthma

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE).

23 Apr 2021

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

23 Apr 2021

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.

23 Apr 2021

Allergies News and Research

Latest Allergies News and Research

Defective epithelial barrier responsible for up to two billion chronic diseases

New method for qualifying safe drug dosing regimens in pediatrics

Study: Second vaccine dose still makes organ transplant recipients vulnerable to COVID-19

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health

Asthma Awareness: Fighting Asthma in 2021

New testing technology can accurately differentiate between viral and bacterial infections

ATS publishes new clinical practice guideline on community-acquired pneumonia

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Risk factors for long COVID-19 in children

Texas A&M AgriLife receives grant to support research on bacteriophage therapy

Immunocompromised children and young adults may experience prolonged SARS-CoV-2 infection

Long COVID also affects children, study finds

Clinical trial to test existing antibiotic for treating serious S. aureus infections begins

Heat treatment for less than a second completely inactivates SARS-CoV-2

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

Corticosteroids not recommended to treat smell loss due to Covid-19, study shows

Study to evaluate how people with immune system deficiencies respond to COVID-19 vaccination

NIAID establishes a clinical research network to improve understanding of childhood asthma

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models

Innovation in neuroscience drug discovery - eBook eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Allergies News and Research

Latest Allergies News and Research

Innovation in neuroscience drug discovery - eBook eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in